论文部分内容阅读
目的 比较 3组不同联合化疗方案对晚期非小细胞肺癌的疗效和毒性。方法 统计分析用NP(长春瑞宾、顺铂 )方案、MVP(丝裂霉素、长春地辛、顺铂 )方案及CAP(环磷酰胺、阿霉素、顺铂 )方案治疗的 89例晚期非小细胞肺癌的临床资料。 结果 有效率为 46 .4%( 13/2 8)。MVP组有效率为 40 %( 12 /30 ) ,CAP组有效率为 2 9%( 9/31) ,毒副反应主要为可耐受的骨髓抑制。结论 NP方案及MVP方案均为治疗晚期非小细胞肺癌较为安全有效的化疗方案。
Objective To compare the efficacy and toxicity of three different combinations of chemotherapy regimens for advanced non-small cell lung cancer. Methods Statistical analysis of 89 cases treated with NP (vinorelbine, cisplatin) regimen, MVP (mitomycin, vindesine, cisplatin) regimen, and CAP (cyclophosphamide, doxorubicin, cisplatin) regimen Clinical data of non-small cell lung cancer. The effective rate was 46.4% (13/2 8). The effective rate in the MVP group was 40% (12/30), and the effective rate in the CAP group was 29% (9/31). The toxic side effects were mainly tolerable myelosuppression. Conclusion Both NP regimen and MVP regimen are safe and effective chemotherapy regimens for advanced non-small cell lung cancer.